<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37534622</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infection.</ArticleTitle><Pagination><StartPage>e17376</StartPage><MedlinePgn>e17376</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e17376</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.202317376</ELocationID><Abstract><AbstractText>SARS-CoV-2 acute respiratory distress syndrome (ARDS) induces uncontrolled lung inflammation and coagulopathy with high mortality. Anti-viral drugs and monoclonal antibodies reduce early COVID-19 severity, but treatments for late-stage immuno-thrombotic syndromes and long COVID are limited. Serine protease inhibitors (SERPINS) regulate activated proteases. The myxoma virus-derived Serp-1 protein is a secreted immunomodulatory serpin that targets activated thrombotic, thrombolytic, and complement proteases as a self-defense strategy to combat clearance. Serp-1 is effective in multiple animal models of inflammatory lung disease and vasculitis. Here, we describe systemic treatment with purified PEGylated Serp-1 as a therapy for immuno-coagulopathic complications during ARDS. Treatment with PEGSerp-1 in two mouse-adapted SARS-CoV-2 models in C57Bl/6 and BALB/c mice reduced lung and heart inflammation, with improved outcomes. PEGSerp-1 significantly reduced M1 macrophages in the lung and heart by modifying urokinase-type plasminogen activator receptor (uPAR), thrombotic proteases, and complement membrane attack complex (MAC). Sequential changes in gene expression for uPAR and serpins (complement and plasminogen inhibitors) were observed. PEGSerp-1 is a highly effective immune-modulator with therapeutic potential for severe viral ARDS, immuno-coagulopathic responses, and Long COVID.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Liqiang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yize Henry</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0003-1721-741X</Identifier><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kibler</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2914-7319</Identifier><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraberger</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varsani</LastName><ForeName>Arvind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Evolution and Medicine, School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turk</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmadbouly</LastName><ForeName>Nora</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aliskevich</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spaccarelli</LastName><ForeName>Laurel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estifanos</LastName><ForeName>Bereket</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enow</LastName><ForeName>Junior</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanetti</LastName><ForeName>Isabela Rivabem</ForeName><Initials>IR</Initials><Identifier Source="ORCID">0000-0002-3441-5955</Identifier><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldevar</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Efrem</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlievert</LastName><ForeName>Jessika</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0006-8886-2183</Identifier><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Browder</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Anjali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juan</LastName><ForeName>Fernando Arcos</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinteric</LastName><ForeName>Aubrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Aman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monder</LastName><ForeName>Henna</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0001-5721-112X</Identifier><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saju</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0005-4590-6572</Identifier><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisriel</LastName><ForeName>Savanah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pathology &amp; Lab Medicine, Yale-New Haven Hospital, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Bertram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karr</LastName><ForeName>Timothy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegenerative Disease Research Center &amp; Proteomics Center, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florsheim</LastName><ForeName>Esther Borges</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>New Jersey Institute of Technology, Newark, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallen</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Colt Advisors LLC, Las Vegas, NV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Masmudur</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7177-819X</Identifier><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McFadden</LastName><ForeName>Grant</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2556-3526</Identifier><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogue</LastName><ForeName>Brenda G</ForeName><Initials>BG</Initials><Identifier Source="ORCID">0000-0002-4545-9208</Identifier><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Applied Structural Discovery, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>Alexandra R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-5195-1442</Identifier><AffiliationInfo><Affiliation>Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI080607</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR074627</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015843">Serpins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015843" MajorTopicYN="Y">Serpins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">serpin</Keyword><Keyword MajorTopicYN="N">uPAR</Keyword></KeywordList><CoiStatement>Serpass Biologics, Inc.&#x2014;Serpass Biologics is a new start&#x2010;up company at ASU, Biodesign Institute, and has provided no funding toward this research or to Dr Lucas and Dr Zhang. Drs Lucas, Zhang, and Wallen are co&#x2010;inventors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37534622</ArticleId><ArticleId IdType="pmc">PMC10493584</ArticleId><ArticleId IdType="doi">10.15252/emmm.202317376</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acanfora D, Acanfora C, Ciccone MM, Scicchitano P, Bortone AS, Uguccioni M, Casucci G (2021) The cross&#x2010;talk between thrombosis and inflammatory storm in acute and long&#x2010;COVID&#x2010;19: therapeutic targets and clinical cases. Viruses 13: 1904</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8540492</ArticleId><ArticleId IdType="pubmed">34696334</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K et&#xa0;al (2021) Symptoms, complications and management of long COVID: a review. J R Soc Med 114: 428&#x2013;442</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre AB, Zhang L, Nix JD, Elmadbouly N, Lucas AR, Wilson&#x2010;Rawls J, Rawls A (2022) Myxomavirus Serp&#x2010;1 protein ameliorates inflammation in a mouse model of Duchenne Muscular Dystrophy. Biomedicines. 10: 1154</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9138346</ArticleId><ArticleId IdType="pubmed">35625891</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Derde L, Al&#x2010;Beidh F, Annane D, Arabi Y, Beane A, van Bentum&#x2010;Puijk W, Berry L, Bhimani Z, Bonten M et&#xa0;al (2020) Effect of hydrocortisone on mortality and organ support in patients with severe COVID&#x2010;19. The REMAP&#x2010;CAP COVID&#x2010;19 corticosteroid domain randomized clinical trial. JAMA 324: 1317&#x2013;1329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Attwood BMS, Morley A, Elvers KT, McKernon J, Donald C, Oates A, Noel A, MacGowan A, Maskell NA et&#xa0;al (2021) Predicting outcomes of COVID&#x2010;19 from admission biomarkers: a prospective UK cohort study. Emerg Med J 38: 543&#x2013;548</Citation><ArticleIdList><ArticleId IdType="pubmed">34021028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouton MC, Geiger M, Sheffield WP, Irving JA, Lomas DA, Song S, Satyanarayanan RS, Zhang L, McFadden G, Lucas AR (2023) The under&#x2010;appreciated world of the serpin family of serine protease inhibitors. EMBO Mol Med 15: e17144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10245030</ArticleId><ArticleId IdType="pubmed">37158379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley BT, Bryan A (2019) Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella . Semin Diagn Pathol 36: 152&#x2013;159</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125557</ArticleId><ArticleId IdType="pubmed">31054790</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruina S, Bos LD, van Roonb MA, Tuip&#x2010;de Boer AM, Schuurmand AR, Koel&#x2010;Simmelinckc MJA, Bogaarde HJ, Tuinmanf PR, van Agtmael MA, Hamanng J et&#xa0;al (2021) Clinical features and prognostic factors in Covid&#x2010;19: a prospective cohort study. EBioMedicine 67: 103378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118723</ArticleId><ArticleId IdType="pubmed">34000622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD (2011) Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 52: e14&#x2013;e17</Citation><ArticleIdList><ArticleId IdType="pubmed">21288835</ArticleId></ArticleIdList></Reference><Reference><Citation>Calore EE, Uip DE, Perez NM (2011) Pathology of the swine&#x2010;origin influenza A (H1N1) flu. Pathol Res Pract 207: 86&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pubmed">21176866</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Zheng D, Abbott J, Liu L, Bartee MY, Long M, Davids J, Williams J, Feldmann H, Strong J et&#xa0;al (2013) Myxomavirus serpin modulates protease pathways and prolongs survival in lethal herpesviral infection. Antimicrob Agents Chemother 57: 4114&#x2013;4127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3754305</ArticleId><ArticleId IdType="pubmed">23774438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Lonati P, Grossi C, Borghi MO, Novembrino C et&#xa0;al (2021) Complement activation and endothelial perturbation parallel COVID&#x2010;19 severity and activity. J Autoimmun 116: 102560</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598768</ArticleId><ArticleId IdType="pubmed">33139116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai E, Viswanathan K, Sun YM, Li X, Liu L, Togonu&#x2010;Bickersteth J, Richardson J, Macaulay C, Nash P, Turner P et&#xa0;al (2006) Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 281: 8041&#x2013;8050</Citation><ArticleIdList><ArticleId IdType="pubmed">16407226</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Alonzo D, De Fenza M, Pavone V (2020) COVID&#x2010;19 and pneumonia: a role for the uPA/uPAR system. Drug Discov Today 25: 1528&#x2013;1534</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299864</ArticleId><ArticleId IdType="pubmed">32562843</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon CT, Xu J, Lupu F (2011) Innate immunity and coagulation. J Thromb Haemost 9: 182&#x2013;188</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151110</ArticleId><ArticleId IdType="pubmed">21781254</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleetwood AJ, Achuthan A, Schultz H, Nansen A, Almholt K, Usher P, Hamilton JA (2014) Urokinase plasminogen activator is a central regulator of macrophage three dimensional invasion, matrix degradation, and adhesion. J Immunol 192: 3540&#x2013;3547</Citation><ArticleIdList><ArticleId IdType="pubmed">24616477</ArticleId></ArticleIdList></Reference><Reference><Citation>Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VEA, Meijers JCM, Brandjes DPM, van Gorp ECM (2012) Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol 84: 1680&#x2013;1696</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166625</ArticleId><ArticleId IdType="pubmed">22930518</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Yaron JR, Wallen JW III, Browder KF, Boyd R, Olson TL, Burgin M, Ulrich P, Aliskevich E, Schutz LN et&#xa0;al (2021) PEGylated Serp&#x2010;1 markedly reduces pristane&#x2010;induced experimental diffuse alveolar hemorrhage, altering uPAR distribution and macrophage invasion. Front Cardiovasc Med 8: 633212</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921738</ArticleId><ArticleId IdType="pubmed">33665212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan SC (2021) Innate and adaptive immune responses to SARS&#x2010;CoV&#x2010;2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol 204: 310&#x2013;320</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013613</ArticleId><ArticleId IdType="pubmed">33534923</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnaukhova E (2022) C1&#x2010;inhibitor: structure, functional diversity and therapeutic development. Curr Med Chem 29: 467&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pubmed">34348603</ArticleId></ArticleIdList></Reference><Reference><Citation>Keragala CB, Medcalf RL (2021) Plasminogen: an enigmatic zymogen. Blood 137: 2881&#x2013;2889</Citation><ArticleIdList><ArticleId IdType="pubmed">33735914</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskinidou C, Vassiliou AG, Zacharis A, Jahaj E, Gallos P, Dimopoulou I, Orfanos SE, Kotanidou A (2021) Endothelial, immunothrombotic, and inflammatory biomarkers in the risk of mortality in critically Ill COVID&#x2010;19 patients: the role of dexamethasone. Diagnostics (Basel) 11: 1249</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8304647</ArticleId><ArticleId IdType="pubmed">34359331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Hyun Kim J, Halfmann P, Hatta M et&#xa0;al (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319&#x2013;323</Citation><ArticleIdList><ArticleId IdType="pubmed">17230189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtovic L, Beeson JG (2021) Complement factors in COVID&#x2010;19 therapeutics. Trends Immunol 42: 94&#x2013;103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733687</ArticleId><ArticleId IdType="pubmed">33402318</ArticleId></ArticleIdList></Reference><Reference><Citation>Leist SR, Dinnon KH III, Scha&#xa8; fer A, Tse LV, Okuda K, Hou YJ, West A, Edwards CE, Sanders W, Fritch EJ et&#xa0;al (2020) Mouse&#x2010;adapted SARS&#x2010;CoV&#x2010;2 induces acute lung injury and mortality in standard laboratory mice. Cell 183: 1070&#x2013;1085.e12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510428</ArticleId><ArticleId IdType="pubmed">33031744</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, Thachil J (2020) Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy &#x2013; either, neither, or both. Semin Thromb Hemost 46: 781&#x2013;784</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645819</ArticleId><ArticleId IdType="pubmed">32512589</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, Thachil J, Iba T, Levy JH (2020) Coagulation abnormalities and thrombosis in patients with COVID&#x2010;19. Lancet Haematol 7: e438&#x2013;e440</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213964</ArticleId><ArticleId IdType="pubmed">32407672</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rennera DM, Comara CE, Whelana JN, Reyes HM, Cardenas&#x2010;Diazc FL, Truitt R, Tan LH, Dong B, Alysandratos KD et&#xa0;al (2021) SARS&#x2010;CoV&#x2010;2 induces double&#x2010;stranded RNA&#x2010;mediated innate immune responses in respiratory epithelial&#x2010;derived cells and cardiomyocytes. Proc Natl Acad Sci USA 118: e2022643118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072330</ArticleId><ArticleId IdType="pubmed">33811184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomas DA, Evans DL, Upton C, McFadden G, Carrell RW (1993) Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem 268: 516&#x2013;521</Citation><ArticleIdList><ArticleId IdType="pubmed">8416956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas AR, McFadden G (2004) Secreted immuno&#x2010;modulatory viral proteins as novel biotherapeutics. J Immunol 173: 4765&#x2013;4774</Citation><ArticleIdList><ArticleId IdType="pubmed">15470015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas A, Liu L&#x2010;Y, Macen J, Nash P, Dai E, Stewart M, Graham K, Etches W, Boshkov L, Nation PN et&#xa0;al (1996) Virus&#x2010;encoded serine proteinase inhibitor SERP&#x2010;1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 94: 2890&#x2013;2900</Citation><ArticleIdList><ArticleId IdType="pubmed">8941118</ArticleId></ArticleIdList></Reference><Reference><Citation>Macen JL, Upton C, Nation N, McFadden G (1993) SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 195: 348&#x2013;363</Citation><ArticleIdList><ArticleId IdType="pubmed">8337817</ArticleId></ArticleIdList></Reference><Reference><Citation>Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH et&#xa0;al (2009) Transmission and pathogenesis of swine&#x2010;origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484&#x2013;487</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953552</ArticleId><ArticleId IdType="pubmed">19574347</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado E, Tao D, Mackey K (2020) Antithrombotic therapies in COVID&#x2010;19 disease: a systematic review. J Gen Intern Med 35: 2698&#x2013;2670</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299557</ArticleId><ArticleId IdType="pubmed">32556875</ArticleId></ArticleIdList></Reference><Reference><Citation>Memoli MJ, Tumpey TM, Jagger BW, Dugan VG, Sheng Z&#x2010;M, Qi L, Kash JC, Taubenberger JK (2009) An early &#x2018;classical&#x2019; swine H1N1 influenza virus shows similar pathogenicity to the 1918 pandemic virus in ferrets and mice. Virology 393: 338&#x2013;345</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763968</ArticleId><ArticleId IdType="pubmed">19733889</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir N, D'Amico A, Dasher J, Tolwani A, Valentine V (2021) Understanding the Andromeda strain &#x2013; the role of cytokine release, coagulopathy and&#xa0;antithrombin III in SARS&#x2010;CoV2 critical illness. Blood Rev 45: 100731</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832361</ArticleId><ArticleId IdType="pubmed">32829961</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA Jr, Mann BJ (2020) Evaluation of K18&#x2010;hACE2 mice as a model of SARS&#x2010;CoV&#x2010;2 infection. Am J Trop Med Hyg 103: 1215&#x2013;1219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470527</ArticleId><ArticleId IdType="pubmed">32723427</ArticleId></ArticleIdList></Reference><Reference><Citation>Munuswamy&#x2010;Ramanujam G, Dai E, Liu L, Shnabel M, Sun YM, Bartee M, Lomas DA, Lucas AR (2010) Neuroserpin, a thrombolytic serine protease&#xa0;inhibitor (serpin), blocks transplant vasculopathy with associated modification of T&#x2010;helper cell subsets. Thromb Haemost 103: 545&#x2013;555</Citation><ArticleIdList><ArticleId IdType="pubmed">20135065</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima N, Sato Y, Katano H, Hasegawa H, Kumasaka T, Hata S, Tanaka S, Amano T, Kasai T, Chong J&#x2010;M et&#xa0;al (2012) Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection. Mod Pathol 25: 1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">21874012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash P, Lucas A, McFadden G (1997) SERP&#x2010;1, a poxvirus&#x2010;encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. Adv Exp Med Biol 425: 195&#x2013;205</Citation><ArticleIdList><ArticleId IdType="pubmed">9433502</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls JM, Poon LLM, Lee CK, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W et&#xa0;al (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361: 1737&#x2013;1778</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112492</ArticleId><ArticleId IdType="pubmed">12781536</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli C, Borotto E, Beverina I, Punzi V, Radrizzani D, Brando B (2021) Heparin dosage, level, and resistance in SARS&#x2010;CoV2 infected patients in intensive care unit. Int J Lab Hematol 43: 1284&#x2013;1290</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251410</ArticleId><ArticleId IdType="pubmed">33855802</ArticleId></ArticleIdList></Reference><Reference><Citation>Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, Elalamy I, Hoppensteadt D, Gerotziafas GT (2018) Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies. Clin Appl Thromb Hemost 24: 8S&#x2013;28S</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710154</ArticleId><ArticleId IdType="pubmed">30296833</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G (2021) Immunity, endothelial injury and complement&#x2010;induced coagulopathy in COVID&#x2010;19. Nat Rev Nephrol 17: 46&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>von Ranke FM, Zanetti G, Hochhegger B, Marchiori E (2013) Infectious diseases causing diffuse alveolar hemorrhage in immunocompetent patients: a state&#x2010;of&#x2010;the&#x2010;art review. Lung 191: 9&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102311</ArticleId><ArticleId IdType="pubmed">23128913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardif J&#x2010;C, L'Allier PL, Gr&#xe9;goire J, Ibrahim R, McFadden G, Kostuk W, Knudtson M, Labinaz M, Waksman R, Pepine CJ et&#xa0;al (2010) A phase 2, double&#x2010;blind, placebo&#x2010;controlled trial of a viral Serpin (Serine Protease Inhibitor), VT&#x2010;111, in patients with acute coronary syndrome and stent implant. Circ Cardiovasc Interv 3: 543&#x2013;548</Citation><ArticleIdList><ArticleId IdType="pubmed">21062996</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate MD, Schilter HC, Brooks AG, Reading PC (2011) Responses of mouse airway epithelial cells and alveolar macrophages to virulent and avirulent strains of Influenza A virus. Viral Immunol 24: 77&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pubmed">21449718</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro JR (2015) The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr Top Microbiol Immunol 386: 3&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">25267464</ArticleId></ArticleIdList></Reference><Reference><Citation>The PHOSP&#x2010;COVID Collaborative Group (2022) Clinical characteristics with inflammation profiling of long COVID and association with 1&#x2010;year recovery following hospitalization in the UK: a prospective observational study. Lancet Respir Med 10: 761&#x2013;775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group (2020) Dexamethasone in hospitalized patients with Covid&#x2010;19 &#x2013; preliminary report. N Engl J Med 383: 2030&#x2013;2040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan K, Richardson J, Togonu&#x2010;Bickersteth B, Dai E, Liu L, Vatsya P, Sun Y&#x2010;M, Yu J, Munuswamy&#x2010;Ramunujam G, Baker H et&#xa0;al (2009) Myxoma viral serpin, serp&#x2010;1, inhibits human monocyte activation through regulation of actin binding protein Filamin B. J Leukoc Biol 85: 418&#x2013;426</Citation><ArticleIdList><ArticleId IdType="pubmed">19052145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Yu C, Jing H, Wu X, Novakovic VA, Xie R, Shi J (2022) Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol 12: 861703</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A (2004) Innate immune response I Th1 and Th2 &#x2010;dominant mouse strains. Shock 22: 460&#x2013;466</Citation><ArticleIdList><ArticleId IdType="pubmed">15489639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettstein L, Weil T, Conzelmann C, M&#xfc;ller JA, Gro&#xdf; R, Hirschenberger M, Seidel A, Klute S, Zech F, Bozzo CP et&#xa0;al (2021) Alpha&#x2010;1 antitrypsin inhibits TMPRSS2 protease activity and SARS&#x2010;CoV&#x2010;2 infection. Nat Commun 12: 1726</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979852</ArticleId><ArticleId IdType="pubmed">33741941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong L&#x2010;YR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Pezzulo AA, Szachowicz PJ, Klumpp K, Aswad F et&#xa0;al (2022) Eicosanoid signalling blockade protects middle&#x2010;aged mice from severe COVID&#x2010;19. Nature 605: 146&#x2013;151</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9783543</ArticleId><ArticleId IdType="pubmed">35314834</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaron JR, Zhang L, Guo Q, Burgin M, Schutz LN, Awo E, Wise L, Krause KL, Ildefonso CJ, Kwiecien JM et&#xa0;al (2020) Deriving immune modulating drugs from viruses &#x2013; a new class of biologics. J Clin Med 9: 1&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7230489</ArticleId><ArticleId IdType="pubmed">32244484</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaron JR, Zhang L, Guo Q, Haydel SE, Lucas AR (2021) Fibrinolytic serine proteases, therapeutic serpins and inflammation: fire dancers and firestorms. Front Cardiovasc Med 8: 648947</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8044766</ArticleId><ArticleId IdType="pubmed">33869309</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ (2021) Long COVID or post&#x2010;COVID&#x2010;19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (London) 53: 737&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Liu S&#x2010;L (2019) Emerging role of LY6E in virus&#x2013;host interactions. Viruses 11: 1020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893646</ArticleId><ArticleId IdType="pubmed">31684192</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Zhang X, Zhao B, Wang J, Zhu Z, Teng Z, Shao J, Shen J, Gao Y, Yuan Z et&#xa0;al (2011) Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL&#x2010;10 and IL&#x2010;6. PloS One 6: e28680</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235144</ArticleId><ArticleId IdType="pubmed">22174866</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Murthy V, Liu S&#x2010;L (2019) Relating GPI&#x2010;anchored Ly6 proteins uPAR and CD59 to viral infection. Viruses 11: 1060</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893729</ArticleId><ArticleId IdType="pubmed">31739586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Yaron JR, Tafoya AM, Wallace SE, Kilbourne J, Haydel S, Rege K, McFadden G, Lucas A (2019) A virus&#x2010;derived immune modulating serpin accelerates wound closure with improved collagen remodeling. J Clin Med 8: 1626</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6832452</ArticleId><ArticleId IdType="pubmed">31590323</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, Madison JA, Knight JS, Kanthi Y, Lawrence DA (2021) Plasma tissue plasminogen activator and plasminogen activator inhibitor&#x2010;1 in hospitalized COVID&#x2010;19 patients. Sci Rep 11: 1580</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810990</ArticleId><ArticleId IdType="pubmed">33452298</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>